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þ CD38 À CML (stem) cells compared with cultures initiated with the CD38 þ subset of lin À CD34 þ cells is markedly enhanced (410-fold) when conditions of reduced growth factor stimulation are used. Quantitative analysis of genes expressed in these different CML subsets revealed a differentiation-associated decrease in IL-3 and G-CSF transcripts, a much more profound decrease in expression of BCR-ABL than predicted by changes in BCR expression, decreasing expression of ABCB1/MDR and ABCG2 and increasing expression of OCT1. p210
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Introduction
Chronic myeloid leukemia (CML) is sustained by an expanding population of leukemic stem cells that have acquired a BCR-ABL fusion gene. 1 The encoded 210 kDa oncoprotein (p210 BCR-ABL ) has constitutively elevated tyrosine kinase activity 2 and this causes an array of biochemical changes that affect the growth factor dependence, turnover and genomic stability of primitive CD34 þ leukemic cells but have little impact on their ultimate differentiation. 3, 4 As a result, in chronic phase CML, excessive numbers of leukemic precursor cells are produced and these generate variably increased numbers of morphologically and functionally normal mature leukemic progeny. Most patients with chronic phase CML also contain a large persisting polyclonal population of normal hematopoietic stem cells which frequently outnumber the leukemic stem cells responsible for propagating the CML clone. 3, [5] [6] [7] Imatinib mesylate (IM) is the first of a series of new drugs designed to target the BCR-ABL-encoded kinase, all of which have shown great initial promise in the treatment of chronic phase patients. [8] [9] [10] [11] However, there is a growing body of evidence that the chronic phase CML stem cells may be less sensitive to these agents than the bulk of the CML cells [12] [13] [14] [15] and hence their use may have a limited ability to prevent the development of mutant subclones, particularly in patients who have acquired larger numbers of leukemic stem cells before being diagnosed.
The present study was designed to investigate a number of properties of CML stem cells that might be expected to underlie their relative insensitivity to IM and potentially other agents in vivo. First, we compared the toxicity of IM on the CD38
À and CD38 þ subsets of lin À CD34 þ chronic phase CML cells maintained under growth factor-reduced as well as growth factor-replete conditions. Then, we compared the expression of several genes in different subsets of primitive and/or quiescent chronic phase CML cells that might be implicated in affecting their responsiveness to IM and other agents. The results indicate that primitive CML cells are altered in ways that would contribute to their possession of a broadly resistant phenotype achieved through multiple mechanisms.
Materials and methods

Cells
Heparin-treated blood, leukapheresis cells and bone marrow cells were obtained from 18 CML patients with high white blood cell counts (Table 1) . Additional samples were obtained from eight CML patients with accelerated phase disease and from two with myeloid blast phase disease. None of the patients had been treated with IM or other BCR-ABL-targeted therapies. Except where indicated otherwise, all experiments performed on CML cells made use of cells from the eight chronic phase specimens in which the long-term culture-initiating cells (LTC-ICs) were predominantly Philadelphia-positive (Ph þ )/BCR/ABL þ (Table 1) . Low-density cells and, in some cases, lin À (CD34 þ -enriched) cells were isolated before their cryopreservation. 16 Normal adult bone marrow cells were from harvests of cells for allogeneic transplants or cadaveric donors (Northwest Tissue Center, Seattle, WA, USA). In all cases, informed consent was obtained and the procedures used were approved by the Research Ethics Board of the University of British Columbia. Lineage markernegative (lin
À cells were isolated using a FACStarPlus or FACSVantage (Becton Dickinson, San Jose, CA, USA). 17 G 0 and G 1 /S/G 2 /M subsets were isolated after staining lin À cells for 45 min at 371C in 10 mM Hoechst 33342 (Hst, Molecular Probes, Eugene, OR, USA) then for another 45 min at 371C with 5 mg/ml Pyronin Y (Py, Sigma Chemical Co., St Louis, MO, USA) and finally with anti-CD34-fluorescein isothiocyanate (FITC) for 20 min, before washing in the continuing presence of 10 mM Hst and 2.5 mg/ml Py plus 1 mg/ml propidium iodide. 16, 18 Pure granulocytes were obtained from pelleted-blood samples after lysis of the red blood cells with buffered ammonium chloride. BaF3 cells expressing doxycycline-regulated BCR-ABL were maintained and cultured in the presence or absence of IM as described. 19 
Suspension cultures
þ cells were collected in serumfree medium (Iscove's medium supplemented with bovine serum albumin, insulin, transferrin and low-density lipoproteins, BIT (StemCell Technologies, Vancouver, BC, Canada) and 10 À4 M 2-mercaptoethanol (Sigma) and aliquots of 5 Â 10 4 cells were then added to each well of a 24-well plate with or without IM (Novartis, Basel, Switzerland) and with or without the following purified recombinant human growth factors: 20 ng/ml interleukin-3 (IL-3, Novartis), 20 ng/ml IL-6 (Cangene, Mississauga, ON, Canada), 20 ng/ml granulocyte colony-stimulating factor (G-CSF) (StemCell Technologies), 100 ng/ml flt3-ligand (Immunex Corp., Seattle, WA, USA) and 100 ng/ml Steel factor (Stem Cell Technologies). Viable cell numbers were determined by hemocytometer counts of trypan blue-excluding cells. For morphological analysis, aliquots were cytospun onto slides and stained with Wright-Giemsa.
Fluorescence in situ hybridization
Aliquots of approximately 2000 cells in 200 ml of phosphatebuffered saline with 2% fetal calf serum were centrifuged at 1000 r.p.m. for 5 min. The pelleted cells were then resuspended in hypotonic KCl (0.075 mol/l) and placed on poly-L-lysine (Sigma)-pretreated slides. A drop of 20% fixative (3:1 methanol/ glacial acetic acid) in hypotonic KCl was added for 3 min, and the slides then immersed in fixative for 15 min before being dried on wet paper towels on a 401C slide warmer. The fixed cells were then pretreated in 2 Â sodium saline citrate for 1 h at 371C, dehydrated in an ethanol series (2 min each in 70, 85% and absolute ethanol) and hybridized with a dual-fusion probe for BCR-ABL according to the manufacturer's instruction (Vysis Inc., Downers Grove, IL, USA). Interphase nuclei were evaluated under a Â 63 oil immersion lens on a Zeiss axioplan microscope using 4 0 ,6-diamidino-2-phenylindole/orange/green filters and images captured with a CCD camera and imaging system (Applied Imaging, San Jose, CA, USA).
cDNA cloning and in vitro transcription of BCR-ABL cDNA
A full-length BCR-ABL cDNA was released by EcoRI digestion from an MSCV-BCR-ABL-IRES-GFP retroviral vector 20 and cloned into a pCR2.1-TOPO vector with a T7 promoter (Invitrogen, Burlington, ON, Canada). The construct was then verified by restriction enzyme digestion analysis. The BCR-ABL plasmid was isolated using the Maxi Prep Kit (Qiagen, Hilden, Germany), verified by restriction enzyme digestion and sequencing, linearized by restriction enzyme digestion and transcribed to generate sense RNA transcripts using the T7 MEGAScript Transcription Kit (Ambion, Austin, TX, USA). 21 Briefly, the RNA was treated with RNAse-free DNAse and recovered by lithium chloride precipitation as suggested by the manufacturer. RNA concentrations were determined by a Ribogreen assay (Molecular Probes) and absorbance measured at OD260 using a Genequant II spectrophotometer (Pharmacia, Orangeville, ON, Canada). Two micrograms of transcribed RNA were separated on a 1.2% agarose gel to ensure that each standard RNA template was a single, pure species, free of DNA contamination. Based on the length of each transcript, the molar mass was calculated and converted into the number of transcripts per microgram of RNA (transcript number/mg RNA ¼ no./(transcript length Â molecular weight), where molecular weight ¼ 340 Â 10 6 mg/mol and no. ¼ Avogadro's number).
Quantitative real-time (Q-RT) PCR analyses
RNA extraction buffer from the Absolutely RNA Microprep kit (Stratagene, La Jolla, CA, USA) was added to pelleted test cells and lysates immediately frozen. One or 0.1 mg of the RNA templates prepared from the BCR-ABL cDNA was reverse transcribed with random hexamers in a 20 ml reaction volume using SuperScript II. The cDNA mixture generated was then serially diluted in duplicate down to the equivalent of a single transcript copy. Each (Q-RT)-PCR was performed using 25 ml of 2 Â SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA), 1 ml of 20 pmol/l specific primers, 1-2 ml cDNA and water to a final volume of 50 ml. 0 , and for ABCG2 were 5 0 -GCTTTCTACCTT GTCGAAAACC-3 0 and 5 0 -GAGACCAGGTTTCATGATCCC-3 0 . Optimal reaction conditions for the amplification of these genes were 40 cycles of three-step PCR (941C for 15 s, 601C for 20 s, 721C for 30 s with a single fluorescence measurement) after initial denaturation (941C for 5 min). RT-PCR data were also subjected to melt curve analysis for verification of true target amplicons and absence of primer dimers. Q-RT-PCR and data analysis were performed on an iCycler iQ system, using iCycler iQ Real-time Detection Software (Bio-Rad, Hercules, CA, USA). An absolute standard curve was generated by plotting the threshold cycle values with 95% confidence intervals against the logarithm of the initial transcript numbers. Specific transcript numbers after amplification of the cDNA in test samples were then calculated from the linear regression of the standard curve (Supplementary Figure 1) . The values for BCR-ABL and BCR transcript numbers relative to GAPDH were generated using a mathematical model for the relative quantification of Q-RT-PCR products. 22 
FACS analysis of P-CrkL
Cells were first stained with anti-CD34-phycoerythrin (PE) and anti-CD38-allophycocyanin (Becton Dickinson), washed once, resuspended in cytofix/cytoperm buffer (Becton Dickinson) and incubated for 20 min at room temperature. Cells were then washed with PermWash (Becton Dickinson) and then incubated another 10 min on ice with CytoPerm Plus Buffer (Becton Dickinson). Cells were incubated with CytoFix/CytoPerm again for 5 min and then with 2.5 mg/ml anti-P-CrkL antibody (New England Biolabs, Ipswich, MA, USA) for 30 min at room temperature. One microliter of FITC-conjugated goat anti-rabbit antibody (Sigma) was then added and the cells incubated for another 30 min. Cells were finally washed and suspended in staining buffer before analysis on a FACSAria (Becton Dickinson).
Western analyses
About 1 to 2 Â 10 5 cells were lysed in phosphorylation solubilization buffer (PSB; 50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buffer, 100 mM NaF, 10 mM sodium pyrophosphate, 2 mM Na3VO4, 4 mM ethylenediaminetetraacetic acid) containing 0.5%. Nonidet P-40 as described. 20 Western analyses were performed using a monoclonal anti-ABL antibody (8E9, Pharmingen, Mississauga, ON, Canada), an anti-phosphotyrosine antibody (4G10, Upstate Biotechnology, Lake Placid, NY, USA) and a monoclonal antibody directed against human actin (Sigma).
Statistical analysis
Results are shown as the mean7s.e.m. values obtained in independent experiments. Differences between groups were assessed using the Student's t-test.
Results
The differential sensitivity of chronic phase lin Figure 1 . In view of previous data from studies of BCR-ABL-transduced cell line models indicating that the sensitivity to IM can be reduced in the presence of increasing growth factor stimulation, 8, 23 and the known activation of a weak autocrine mechanism in primitive proliferating CML cells, 16, 17 we also compared the effect of maintaining the cells in an optimal growth factor cocktail versus no added growth factors. All samples were from patients who had never been treated with IM (or any other BCR-ABL-targeted therapeutic) and whose primitive cells had been previously found to be predominantly Ph þ /BCR/ABL þ (n ¼ 5, Table 1 and Figure 1b ). As shown in Figure 2 , the inhibitory effect of IM was much more pronounced (B10 to 20-fold at week 3) in cultures initiated with the more mature lin À CD34 þ CD38 þ cells than in those initiated with the more primitive lin À CD34 þ CD38 À cells and this differential effect was markedly enhanced when exogenous growth factors were not added (200-fold at the 10 mM IM dose, Po0.01). Morphological analysis of the cells recovered at the end of the 3 weeks of incubation in the absence of IM showed that these were predominantly mature myeloid cells, as expected, 24 and this was also true when IM was present (Supplementary Figure 2) . Nevertheless, in both cases Ph 
IL-3 and G-CSF are expressed at higher levels in the most primitive CML cells
We have previously shown that the expression of IL-3 and G-CSF is abnormally upregulated in all CD34 þ chronic phase CML cells except for those that are quiescent, and that this autocrine mechanism then appears to be switched off when the cells begin to terminally differentiate. 16, 17 It was therefore of interest to determine whether the downregulation of this autocrine IL-3/G-CSF mechanism in differentiating CML cells might actually start earlier, given the enhanced IM sensitivity displayed by lin À CD34 þ CD38 þ CML cells (compared with the more primitive lin À CD34 þ CD38 À CML cells) in the absence of exogenously provided growth factors. Q-RT-PCR analyses of FACS-purified subsets of CML cells demonstrated that a significant and progressive decline in IL-3 and G-CSF expression does occur as these cells differentiate in vivo (Figure 3a , Po0.05). IL-3 and G-CSF transcript levels were also found to be consistently higher in the G 1 /S/G 2 /M fraction compared with the G 0 fraction of CD34 þ CML cells (Figure 3b ). This latter result is consistent with the suppressed autocrine activity previously reported for quiescent CML cells obtained from a different set of patient samples. 16 The high sensitivity of the Q-RT-PCR method used here also allowed both IL-3 and G-CSF transcripts to be detected for the first time in normal CD34 þ bone marrow cells, but at significantly lower levels than in the corresponding compartments of CML cells (Figure 3b Figure 4a , we found absolute levels of BCR-ABL transcripts to be consistently very high in the lin À CD34 þ CD38 À compartment, regardless of the genotype of the LTC-ICs they contained. The BCR-ABL transcript levels then progressively and dramatically decreased with increasing differentiation (levels in the lin À CD34 þ CD38 À cells were 100-fold higher than in either the light-density lin þ CD34
À cells or purified circulating leukemic granulocytes, Po0.01). Thus, even when the stem cell-enriched compartment contained a significant proportion of residual normal elements, the overall average level of BCR-ABL transcript levels still appeared much higher than in the later compartments of exclusively leukemic cells.
We were also able to extend previous reports 25, 26 of higher expression of BCR-ABL in comparable subsets of cells from CML patients with more advanced disease, using a method for absolute transcript measurement that allows a more direct comparison between different cell populations. The very low numbers of lin À CD34 þ CD38 À cells present in the samples from our more advanced patients (two in myeloid blast crisis and eight in accelerated phase) precluded subdividing the lin À CD34 þ cells into CD38 þ and CD38 À subsets. Nevertheless, as shown in Figure 4b , we found BCR-ABL transcript levels in the samples from patients with advanced disease were consistently higher in the more primitive (lin À CD34 þ ) subset than in the later (lin þ CD34 À ) cells. Taken together, these findings indicate that the control of BCR-ABL expression in CML cells remains strongly influenced by their differentiation status even after disease progression.
We next asked how the differences in BCR-ABL expression between the most primitive (CD38 À ) and more mature (CD38 þ ) subsets of CD34 þ CML cells would compare with those associated with changes in the cycling status of the same CD34 þ populations. For this analysis, we isolated the G 0 and G 1 /S/G 2 /M fractions of lin À CD34 þ cells from six of the eight chronic phase samples with Ph þ LTC-ICs studied in Figure 4a . BCR-ABL transcript levels were found to be consistently, but only slightly (less than twofold) higher in the G 0 fraction than in the G 1 /S/G 2 /M fraction (Figure 5a ). Thus, differentiation from a CD34 þ CD38 À to a CD34 þ CD38 þ cell appears to be a more important determinant of changes in BCR-ABL expression than exit from the cell cycle per se. Figure 2 The differential IM sensitivity of lin À CD34 þ CD38 À and lin
þ CML cells to IM in vitro is markedly enhanced under growth factor-deprived conditions. Suspension cultures were initiated in triplicate with FACS-purified cells from five different chronic phase CML patients' samples, all with predominantly Ph þ LTC-ICs. The cells were maintained in the presence (a) or absence (b) of growth factors and fresh IM added weekly at the concentrations indicated. After 3 weeks, viable cell yields were determined by hemocytometer counts of trypan blueexcluding cells and then expressed as a percent of the value in the matching control cultures (to which no IM was added). The differences between the results for lin
þ cells are significant (*Po0.01).
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The elevated expression of BCR-ABL in very primitive chronic phase CML cells is not predicted by expression of BCR
As expression of the BCR-ABL fusion gene would be expected to be regulated in cis by the same sequences that regulate BCR, it was of interest to analyze BCR expression in the same extracts used for BCR-ABL gene expression determinations. BCR expression was found to decrease progressively in the more mature CML cells subsets (10-to 15-fold overall, Figure 4c ). BCR transcript levels were also higher in the G 0 compared with the G 1 /S/G 2 /M subset of CD34 þ cells (Btwofold, Figure 5b ). However, the changes in BCR transcript levels indicated a much lower expression in the most primitive (lin Figure 3) , the Westerns still detected significantly higher levels of p210 BCR-ABL oncoprotein in the lin
þ cells (three-to 10-fold, Po0.05) and, as expected, these levels did not change when the cells were incubated overnight in the presence of IM 1-10 mM (Figure 6a) . The lin À CD34 þ CD38 À CML cells also showed greater fluorescence after staining with an anti-P-CrkL antibody by comparison to similarly stained lin À CD34 þ CD38 þ cells from the same five samples of chronic phase CML cells (Figure 6b ). Evidence of a higher p210 BCR-ABL kinase activity in the lin À CD34 þ CD38 À cells was also seen in Western blots probed with an antibody specific for phosphorylated tyrosine residues (data not shown).
BCR-ABL expression levels can regulate the sensitivity of hematopoietic cells to IM
The increased expression and activity of p210 BCR-ABL seen in very primitive CML cells might be expected to explain or at least contribute to their relative insensitivity to IM as also suggested by others. 26 However, other mechanisms might also be differentially operative in different cell types. To formally test the hypothesis that the level of p210 BCR-ABL , alone, can be a determining factor, we evaluated the sensitivity of a BCR-ABLtransduced BaF3 cell line in which the level of expression of p210 BCR-ABL can be variably downregulated by exposure to nontoxic levels of doxycycline, which directs activation of an upstream tet-regulated repressor. 19 The results of these experi- Because the uptake of IM by CML cells is thought to depend, at least in part, on their expression of OCT1, 29, 30 it was also of interest to determine if and how expression of this transporter gene might change during the differentiation of chronic phase CML stem cells. At the same time, we analyzed the expression of two other genes, ABCB1 (MDR) and ABCG2, because the transporters they encode regulate the efflux of many chemotherapeutic agents, 31 and are known to be present at elevated levels in the more primitive types of normal human bone marrow cells.
32 Q-RT-PCR measurements showed that OCT1 transcript levels were highest in the most mature lin þ CD34 À cells and relatively lower (4100-fold less, Po0.01) in the lin À CD34 þ CD38 À compartment of normal bone marrow cells (Figure 8 ). Importantly, we found this trend to be exacerbated in the CML samples where OCT1 transcripts were below the level of detection in two of the four isolates of lin À CD34 þ CD38 À cells examined ( Figure 8 ). As expected, ABCB1 and ABCG2 transcript levels were highest in the lin À CD34 þ CD38 À cells from normal bone marrow but in the CML samples, this trend was enhanced further (Figure 8 ). The combination of a very low expression of OCT1 (low IM uptake) 29, 30 and high expression of ABCB1 (high IM efflux) 30, 33 in a CML stem cell-enriched population suggests additional mechanisms that would be expected to contribute to their relative insensitivity to IM in addition to many conventional chemotherapeutic agents.
Discussion
Until the advent of BCR-ABL-targeted therapy, treatment of most chronic phase CML patients was focused primarily on achieving hematologic control of the disease. However, cytogenetic remissions were rare and progression to acute phase within a few years was the inevitable outcome unless a bone marrow transplant could be performed. The recent introduction of IM therapy has altered this management paradigm and major cytogenetic remissions are now common. [34] [35] [36] Nevertheless, even when karyotypic evidence of leukemic cells is negative, BCR-ABL transcripts typically persist at detectable levels [37] [38] [39] and the resurgent growth of IM-resistant leukemic cells remains a clinical concern. [40] [41] [42] There is thus an emerging imperative to understand the properties of primitive CML cells that determine the response of individual patients to specific treatments.
Recent laboratory studies have suggested that the most primitive and/or quiescent fraction of chronic phase CML cells are relatively insensitive to doses of IM that kill the more mature leukemic cells and a similar finding may apply to other BCR-ABL-targeted agents. 12, 15 We now show that the CML stem cell population is uniquely characterized by an elevated expression of BCR-ABL mRNA, protein and kinase activity, as well as an elevated expression of IL-3 and G-CSF, a highly suppressed expression OCT1 and an elevated expression of ABCB1 and ABCG2. This combination of phenotypic alterations could thus provide several mechanisms to account for a greater innate resistance of CML stem cells to IM and likely other therapeutic agents. Importantly, we demonstrate that the elevated expression of BCR-ABL and IL-3 and G-CSF are all more tightly correlated with the primitive status of the cells rather than with their quiescence. The mechanism(s) responsible for the increased level of BCR-ABL message and protein found in CML stem cells are not immediately apparent, given the modest increases in expression of the normal BCR allele seen in the same cell extracts. One possibility is that new sequences in, or downstream of, the ABL component of the fusion gene may selectively alter the rate of transcription of the BCR-ABL gene in CML stem cells. Alternatively, BCR-ABL transcripts may have decreased rates of degradation or the BCR-ABL oncoprotein may exert autopromotional transcriptional effects that are stem cell restricted. Future experiments will be required to investigate these possibilities. However, regardless of the mechanism ultimately determined, the present findings underscore the likelihood that attempts to kill CML stem cells will require much greater drug concentrations than those sufficient to inactivate their more mature progeny. These results raise the additional novel possibility that other types of cancer stem cells may display similarly deregulated expression of acquired fusion oncogenes.
The present findings also provide an attractive explanation for the stage specificity of the autocrine IL-3/G-CSF mechanism we have previously demonstrated to be active in CD34 þ chronic phase CML cells, 17 but transiently silenced when these cells exit the cell cycle. 16 Here, we show that the levels of IL-3 and G-CSF transcripts are both highest in the CML stem cells and then progressively decrease together even before they leave the CD34 þ CD38 þ compartment. Thus during the differentiation of primitive CML cells, the level of expression of BCR-ABL correlates with the expression of IL-3 and G-CSF. This suggests a direct role of p210 BCR-ABL in activating the autocrine IL-3/G-CSF mechanism, as is also supported by our previous BCR-ABL gene transfer experiments. The latter showed that expression of IL-3 and G-CSF is rapidly activated in both primitive normal human and murine hematopoietic cells following the retrovirally mediated introduction of a BCR-ABL transgene. 20, 43, 44 This changing pattern of growth factor gene expression is also consistent with the acquisition by differentiating CML cells of an increasing sensitivity to IM under conditions where saturating levels of exogenous growth factors are not available, as might be anticipated to occur in vivo.
Furthermore, we found that transcripts for OCT1, a transporter thought to be important for IM uptake, 29, 30 were reduced to levels just at or below the limit of detection in the CD34 þ CD38 À subset compared to later types of CML cells. OCT1 transcript levels have recently been found to be lower in IM non-responder CML patients than in IM responders. 45 The present study suggests that this finding could be explained simply by differences in the numbers of primitive cells present in the two patient subgroups. A particularly low expression of OCT1 in CML stem cells suggests that they might be unable to achieve sufficient intracellular levels of IM to be adversely affected. Conversely, expression of both ABCB1 and ABCG2 was more highly elevated in the same primitive subset, thus extending the recent report of elevated ABCG2 expression in CD34 þ CML cells. 46 ABCB1 is thought to play a role in effluxing IM out of CML cells, 30, 33 which could further enhance the effects of reduced expression of OCT1. The contribution of ABCG2 to the insensitivity of primitive CML cells to IM has been more controversial, although most recent studies indicate that IM suppresses ABCG2 activity rather than vice versa. [46] [47] [48] [49] [50] Nevertheless, increased expression of ABCB1 and ABCG2 would predict an important insensitivity of primitive CML cells to many candidate therapeutic agents that are effluxed by these multisubstrate transporters. 31 Taken together, our findings indicate that CML stem cells are characterized by numerous features that either alone, or in combination, could markedly decrease their ability to be killed by IM and other agents. These considerations highlight the importance of gaining further understanding of the biology and responses of CML stem cells in future efforts to devise therapies with curative potential. They may also be relevant to other types of malignancies that are sustained by transformed stem cell populations. providing patient samples; K Lambie, G Shaw, K Saw, L Zhou, W Y Chan and E Pang for excellent technical assistance; the Terry Fox Laboratory FACS Facility for assistance in cell sorting; the Stem Cell Assay Laboratory for cell processing and cryopreservation of normal and CML samples; D Wytrykush for assistance in preparing the paper; Dr P Lansdorp (Terry Fox Laboratory) and StemCell Technologies (Vancouver, BC, Canada) for antibodies and culture reagents, and Novartis (Basel, Switzerland) for the IM. Resistant phenotype of CML stem cells X Jiang et al
